Menu
Search
|

Menu

Close
X

Dova Pharmaceuticals Inc DOVA.OQ (NASDAQ Stock Exchange Global Market)

9.37 USD
+0.03 (+0.32%)
As of 11:34 AM EDT
chart
Previous Close 9.34
Open 9.24
Volume 11,826
3m Avg Volume 91,982
Today’s High 9.44
Today’s Low 9.24
52 Week High 35.33
52 Week Low 5.62
Shares Outstanding (mil) 28.23
Market Capitalization (mil) 263.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
0
FY16
0
EPS (USD)
FY18
-2.593
FY17
-1.190
FY16
-1.205
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.82
Price to Sales (TTM)
vs sector
25.46
9.06
Price to Book (MRQ)
vs sector
3.45
4.61
Price to Cash Flow (TTM)
vs sector
--
40.52
Total Debt to Equity (MRQ)
vs sector
26.99
17.60
LT Debt to Equity (MRQ)
vs sector
18.26
13.95
Return on Investment (TTM)
vs sector
-93.96
12.09
Return on Equity (TTM)
vs sector
-105.11
13.20

EXECUTIVE LEADERSHIP

Paul Manning
Chairman of the Board, Since 2017
Salary: --
Bonus: --
David Zaccardelli
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Mark Hahn
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Kevin Laliberte
Senior Vice President - Product Development, Since 2017
Salary: --
Bonus: --
Lee Allen
Chief Medical Officer, Since 2017
Salary: $285,221.00
Bonus: $20,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

240 Leigh Farm Rd
DURHAM   NC   27707-8100

Phone: +1919.8064487
Site: dova.com/

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

SPONSORED STORIES